A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency

Inclusion Criteria: * Bone age less than equal to (\</=) 9 years (females) or \</= 11 years (males) as determined by X-ray of the left hand and wrist using Greulich and Pyle method and obtained within the 12 months prior to enrollment * Prepubertal (Tanner I) males and females by physical examination * Diagnosis of GHD (stimulated GH less than \[\<\] 10 nanograms per milliliter \[ng/mL\]) by two standard pharmacologic tests obtained up to 12 months prior to informed consent/assent * Normal thyroid function test within the 12 months prior to informed consent/assent * Normal complete blood counts within 12 months prior to informed consent/assent * Documentation of prior height and weight measurements, with height standard deviation score (SDS) \</= 5th percentile for idiopathic isolated GHD participants Exclusion Criteria: * Any previous rhGH treatment * Short stature etiologies other than GHD * Acute critical illness or uncontrolled chronic illness, which in the opinion of the investigator and medical monitor, would interfere with participation in this study, interpretation of the data, or pose a risk to participant safety * Chronic illnesses such as inflammatory bowel disease, celiac disease, heart disease, and diabetes * Bone diseases such as achondroplasia or hypochondroplasia, intracranial tumor, irradiation, and traumatic brain injury * Participants receiving oral or inhaled chronic corticosteroid therapy (greater than \[\>\] 3 months) for other medical conditions other than central adrenal insufficiency * Participants who require higher (2 times or greater than maintenance) doses of corticosteroids for more than 5 days in the 6 months prior to enrollment in the study * Participants with active malignancy or any other condition that the investigator believes would pose a significant hazard to the participant if rhGH were initiated * Females with Turner syndrome regardless of their GH status * Prader-Willi syndrome regardless of GH status * Born small for gestational age regardless of GH status * Presence of scoliosis requiring monitoring * Previous participation in another clinical trial or investigation of GH, treatment for growth failure, or treatment with a biologic agent * Participants with closed epiphyses * Participants with a known hypersensitivity to somatropin, excipients, or diluent